Drug intelligence / Profile preview

177Lu-B5-IgG4

Development stage: Phase 1
Lead developer: Affiliated Hospital of Jiangnan University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-B5-IgG4 is a radiopharmaceutical that combines lutetium-177 with B5-IgG4 antibody targeting fibronectin ED-B (EDB-FN). It represents an emerging approach in targeted radionuclide therapy (TRT) for solid tumors.

Targets

ED-B (Fibronectin extra domain B)

Beyond the preview

Go deeper on 177Lu-B5-IgG4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-B5-IgG4.

Explore the full profile